Letter to the Editor | Published:

Effect of measurable (‘minimal’) residual disease (MRD) information on prediction of relapse and survival in adult acute myeloid leukemia

Leukemia volume 30, pages 20802083 (2016) | Download Citation

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    , , , , , et al. Resistance prediction in AML: analysis of 4601 patients from MRC/NCRI, HOVON/SAKK, SWOG and MD Anderson Cancer Center. Leukemia 2015; 29: 312–320.

  2. 2.

    , , , , , et al. Effect of genetic profiling on prediction of therapeutic resistance and survival in adult acute myeloid leukemia. Leukemia 2015; 29: 2104–2107.

  3. 3.

    , , , , , et al. A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia. Blood 2013; 121: 4854–4860.

  4. 4.

    , , , , , et al. Allogeneic hematopoietic cell transplantation for acute myeloid leukemia: time to move toward a minimal residual disease-based definition of complete remission? J Clin Oncol 2016; 34: 329–336.

  5. 5.

    , , , , , et al. Pre- and post-transplant quantification of measurable ('minimal') residual disease via multiparameter flow cytometry in adult acute myeloid leukemia. Leukemia 2016; 30: 1456–1464.

  6. 6.

    , , , , , et al. Prediction of early death after induction therapy for newly diagnosed acute myeloid leukemia with pretreatment risk scores: a novel paradigm for treatment assignment. J Clin Oncol 2011; 29: 4417–4423.

  7. 7.

    , , , , , et al. High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42 A study. J Clin Oncol 2013; 31: 3889–3897.

  8. 8.

    , , , , , et al. Prognostic relevance of treatment response measured by flow cytometric residual disease detection in older patients with acute myeloid leukemia. J Clin Oncol 2013; 31: 4123–4131.

  9. 9.

    , , , , , et al. Relation of clinical response and minimal residual disease and their prognostic impact on outcome in acute myeloid leukemia. J Clin Oncol 2015; 33: 1258–1264.

  10. 10.

    , , , , , et al. Early peripheral blood blast clearance during induction chemotherapy for acute myeloid leukemia predicts superior relapse-free survival. Blood 2007; 110: 4172–4174.

  11. 11.

    , , , , , et al. Early clearance of peripheral blasts measured by flow cytometry during the first week of AML induction therapy as a new independent prognostic factor: a GOELAMS study. Leukemia 2009; 23: 350–357.

  12. 12.

    , , , , , et al. Rapid rate of peripheral blood blast clearance accurately predicts complete remission in acute myeloid leukemia. Leukemia 2014; 28: 713–716.

  13. 13.

    , , , , , et al. Prospective comparison of early bone marrow evaluation on day 5 versus day 14 of the ‘3+7’ induction regimen for acute myeloid leukemia. Am J Hematol 2015; 90: 1159–1164.

  14. 14.

    , , , , , et al. Toward optimization of postremission therapy for residual disease-positive patients with acute myeloid leukemia. J Clin Oncol 2008; 26: 4944–4951.

  15. 15.

    , , , , , et al. Assessment of minimal residual disease in standard-risk AML. N Engl J Med 2016; 374: 422–433.

Download references

Acknowledgements

Research reported in this publication was supported by grants from the National Cancer Institute/National Institutes of Health (NCI/NIH; CA182010 to RBW and MO, CA160872 to DLS, and CA090998 to MO). The S0106 study was conducted by SWOG and supported by NIH/NCI/NCTN Grants CA180888, CA180819, CA180828 and CA180944; NCI Grant CA182010, and in part by Wyeth (Pfizer) Pharmaceuticals, Inc. RBW is a Leukemia & Lymphoma Society Scholar in Clinical Research.

Author information

Author notes

    • S H Petersdorf

    Deceased.

Affiliations

  1. SWOG Statistical Center, Fred Hutchinson Cancer Research Center, Seattle, WA, USA

    • M Othus
  2. Division of Hematopathology, Department of Laboratory Medicine, University of Washington, Seattle, WA, USA

    • B L Wood
  3. Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA

    • D L Stirewalt
    • , E H Estey
    • , S H Petersdorf
    • , F R Appelbaum
    •  & R B Walter
  4. Division of Medical Oncology, Department of Medicine, University of Washington, Seattle, WA, USA

    • D L Stirewalt
    • , S H Petersdorf
    •  & F R Appelbaum
  5. Division of Hematology, Department of Medicine, University of Washington, Seattle, WA, USA

    • E H Estey
    •  & R B Walter
  6. Division of Hematology/Oncology, University of Alabama at Birmingham, Birmingham, AL, USA

    • H P Erba
  7. Department of Epidemiology, University of Washington, Seattle, WA, USA

    • R B Walter

Authors

  1. Search for M Othus in:

  2. Search for B L Wood in:

  3. Search for D L Stirewalt in:

  4. Search for E H Estey in:

  5. Search for S H Petersdorf in:

  6. Search for F R Appelbaum in:

  7. Search for H P Erba in:

  8. Search for R B Walter in:

Competing interests

The authors declare no conflict of interest.

Corresponding author

Correspondence to R B Walter.

Supplementary information

About this article

Publication history

Published

DOI

https://doi.org/10.1038/leu.2016.120

Supplementary Information accompanies this paper on the Leukemia website (http://www.nature.com/leu)

Further reading